Patents by Inventor Robert H. Purcell

Robert H. Purcell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190144527
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: January 21, 2019
    Publication date: May 16, 2019
    Inventors: Zhaochun CHEN, Stephen H. LEPPLA, Mahtab MOAYERI, Suzanne U. EMERSON, Robert H. PURCELL
  • Patent number: 10227395
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: February 14, 2014
    Date of Patent: March 12, 2019
    Assignee: The United States of America, as represented by the Secretary, Dept. of Health and Human Services
    Inventors: Zhaochun Chen, Stephen H. Leppla, Mahtab Moayeri, Suzanne U. Emerson, Robert H. Purcell
  • Patent number: 10053503
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: August 21, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
  • Publication number: 20180111981
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: January 20, 2017
    Publication date: April 26, 2018
    Inventors: Zhaochun CHEN, Robert H. PURCELL, Suzanne U. EMERSON, Stephen H. LEPPLA, Mahtab MOAYERI
  • Patent number: 9850468
    Abstract: The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: December 26, 2017
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, ROYAL CORNWALL HOSPITAL TRUST
    Inventors: Suzanne U. Emerson, Priyanka Shukla, Hanh T. Nguyen, Robert H. Purcell, Harry R. Dalton, Richard Bendall
  • Patent number: 9845350
    Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: December 19, 2017
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
  • Patent number: 9815887
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Nowalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: November 14, 2017
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Lisbeth Kim Green, Stanislav Sosnovtsev, Karin Bok
  • Patent number: 9783596
    Abstract: Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: October 10, 2017
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
  • Patent number: 9708392
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: March 19, 2015
    Date of Patent: July 18, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Patricia Earl, Bernard Moss, Suzanne U. Emerson, Robert H. Purcell
  • Publication number: 20170114120
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: March 19, 2015
    Publication date: April 27, 2017
    Inventors: Zhaochun CHEN, Patricia EARL, Bernard MOSS, Suzanne U. EMERSON, Robert H. PURCELL
  • Publication number: 20170066815
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Nowalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 9, 2017
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human
    Inventors: Zhaochun Chen, Robert H. Purcell, Lisbeth Kim Green, Stanislav Sosnovtsev, Karin Bok
  • Patent number: 9580492
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: February 28, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri
  • Patent number: 9534041
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Norwalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: January 3, 2017
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Lisbeth Kim Green, Stanislav Sosnovtsev, Karin Bok
  • Publication number: 20160200803
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Application
    Filed: January 13, 2015
    Publication date: July 14, 2016
    Inventors: Zhaochun CHEN, Robert H. PURCELL, Suzanne U. EMERSON, Stephen H. LEPPLA, Mahtab MOAYERI
  • Publication number: 20160137723
    Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human
    Inventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
  • Publication number: 20160137722
    Abstract: Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.
    Type: Application
    Filed: January 22, 2016
    Publication date: May 19, 2016
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human
    Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
  • Publication number: 20160102296
    Abstract: The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus.
    Type: Application
    Filed: October 20, 2015
    Publication date: April 14, 2016
    Inventors: Suzanne U. Emerson, Priyanka Shukla, Hanh T. Nguyen, Robert H. Purcell, Harry R. Dalton, Richard Bendall
  • Patent number: 9273121
    Abstract: Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 1, 2016
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ana P. Goncalvez, Robert H. Purcell, Ching-Juh Lai
  • Patent number: 9273124
    Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: March 1, 2016
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
  • Publication number: 20160009788
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to a Norovirus. In some embodiments, the Norovirus is a genogroup II Norovirus or a Genogroup II Norovirus. In some embodiments, the Norovirus is Norwalk virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. In addition, the neutralization ability of the disclosed antibodies makes them ideal for treating a subject with a Norovirus infection. Thus, disclosed are methods of treating and/or preventing these infections.
    Type: Application
    Filed: February 11, 2014
    Publication date: January 14, 2016
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human
    Inventors: Zhaochun Chen, Robert H. Purcell, Lisbeth Kim Green, Stanislav Sosnovtsev, Karin Bok